California, Michigan and Florida Lead 2026 State Cannabis Sales

California Holds Top Spot Despite Margin Erosion

California remains the largest legal cannabis market by revenue, but its lead over Michigan and Florida narrowed sharply in the first six months of 2026. The state recorded an estimated $2.1 billion in adult-use and medical sales through June, a 3% decline year-over-year, according to industry tracking data. Price compression drove the drop. So did continued illicit-market competition.

Michigan posted $1.4 billion in sales over the same period, a 19% year-over-year increase, while Florida — which launched adult-use sales in January following the November 2025 ballot measure — tallied $1.2 billion. If current trajectory holds, Florida's six-month run rate suggests it'll challenge Michigan for the #2 slot by year-end.

Michigan's Sustained Growth Defies Saturation Fears

Michigan's market expansion continues unabated despite warnings from analysts that the state would hit saturation by mid-2026. The state added 47 new retail licenses in the first half of the year, bringing the total to 612 active dispensaries. Per-store revenue averaged $2.3 million over the six-month period, down 8% from 2025 but still well above break-even thresholds for most operators.

MSOs with Michigan exposure — Verano, Cresco Labs, and Green Thumb Industries — all reported sequential quarterly revenue gains in the state through Q2 earnings calls. The math is hard to argue with. Michigan's population density in metro Detroit and Grand Rapids supports far more retail density than early models predicted.

Florida's Adult-Use Launch Reshapes the Top 10

Florida's adult-use rollout in January 2026 immediately vaulted the state into the top three, displacing Illinois and Colorado in the rankings. The state issued 210 adult-use licenses to existing medical operators under the expedited conversion framework passed in December 2025. Trulieve, Curaleaf, and Verano captured an estimated 62% of adult-use sales through June, using their existing medical footprints as launchpads.

Florida's six-month sales total of $1.2 billion split roughly 60/40 between adult-use and medical, with medical sales declining 14% as patients migrated to the adult-use channel to avoid the state's $75 annual medical card fee. Under the 15% adult-use tax rate enacted alongside legalization, the state collected an estimated $180 million in excise tax revenue.

Illinois and Colorado Drop in Rankings

Illinois fell to fourth place with $950 million in sales, while Colorado rounded out the top five at $890 million. Both states saw flat-to-declining sales as mature-market dynamics and price deflation offset modest population growth. Illinois operators reported average wholesale prices down 22% year-over-year, pressuring vertically integrated MSOs that rely on cultivation margins.

Colorado's sales decline of 6% year-over-year marks the state's third consecutive year of contraction, a trend attributed to competition from neighboring New Mexico (which launched adult-use sales in April 2022) and continued interstate cannabis tourism headwinds post-pandemic.

The Next Five: Arizona, Nevada, Massachusetts, New York, New Jersey

Arizona, Nevada, Massachusetts, New York, and New Jersey occupied slots six through ten, with combined sales of $2.8 billion. The rankings:

• Arizona: $680 million (down 4% YoY)
• Nevada: $590 million (flat YoY)
• Massachusetts: $570 million (up 7% YoY)
• New York: $510 million (up 140% YoY as retail buildout accelerates)
• New Jersey: $450 million (up 31% YoY)

New York's 140% growth rate reflects the state's ongoing retail expansion, with 187 dispensaries operational by June 2026 compared to 78 at the end of 2025. The state's Office of Cannabis Management projects 400+ licensed retailers by year-end, which would position New York to crack the top five in 2027.

What the Rankings Mean for MSO Strategy

The top-10 shuffle underscores a strategic pivot for multi-state operators: Florida and New York exposure now matters more than legacy Western markets. MSOs with heavy California and Colorado weighting — including Glass House Brands and Schwazze — underperformed peers with diversified Eastern portfolios in Q2 earnings.

Operators that secured Florida licenses in the 2025 conversion window are seeing immediate EBITDA accretion, while those locked out face a two-year wait for the state's next license lottery.

The data also highlights Michigan's durability as a Midwest anchor market. Despite three years of double-digit growth, the state shows no signs of the demand cliff that hit Colorado and Washington in their fifth and sixth years post-legalization.

What to Watch in the Second Half

Three variables will determine whether the top-10 order holds through year-end. First, Florida's sales velocity: if the state sustains its $200M-per-month run rate, it'll overtake Michigan by November. Second, New York's retail buildout: every additional 50 stores adds an estimated $80M in annualized sales. Third, California's illicit-market enforcement: the state's newly funded eradication task force seized 1.2 million plants in Q2, the highest quarterly total since 2019, which could stabilize legal pricing if sustained.

For full background on state market dynamics, see the CannIntel topic hub on state cannabis sales rankings. We'll be tracking Q3 data for signs of Florida's ascent and New York's continued acceleration.